Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

News tone is mixed: company reporting emphasizes year-over-year growth and development progress, while earnings-surprise coverage was negative. A secondary earnings calendar reported an approximately 8.9% next-day decline; the RankAlpha anchor was $32.85 on August 19. Social coverage and robust analyst-revision data are unavailable, so this remains a low-coverage monitoring view.

News tone is mixed-positive: the company delivered a strong beat and upbeat FY2027 outlook, but the post-release reaction was negative, with reported after-hours and premarket declines despite the beat. No reliable post-print analyst rating, estimate, or target revisions were available, and the peer set remains loose because no direct operating comparator was validated in the packet. [#SEC-8K-2026-08-17] [Investing.com market-reaction report](https://ng.investing.com/news/stock-market-news/why-is-fabrinet-stock-sliding-today-93CH-2664144)

The earnings follow-up is cautiously constructive because the company reaffirmed several dated clinical and regulatory milestones and extended runway into 2028. Reported Q2 results cannot be classified as a beat or miss from the available evidence, and analyst revisions, target changes, and trusted attribution of the post-release price reaction are unavailable. Social coverage is absent, so confidence remains moderate despite the stronger deterministic signal.

Headline activity is concentrated around the scheduled 2Q26 reporting cycle, but social, options, short-interest, employee, and trusted post-print analyst data are unavailable. The packet's anchor is $5.42 on August 18; no checked source reliably attributes a subsequent price move to results. Evidence supports monitoring rather than a high-conviction directional call.

Primary-source tone is constructive on Q1 growth and maintained guidance but mixed because cash flow, leverage and PLF trends remain weak. The retrieved Aug. 19 quote was essentially flat around $6.82 versus the Aug. 18 anchor, suggesting limited immediate market reaction. Consensus surprise data and post-print analyst revisions were unavailable; coverage and peer comparability remain moderate to weak.

The T+1 earnings trigger is dated 2026-08-18, while the supplied primary earnings materials are dated 2026-08-11. The latest company update is operationally constructive, but no verified earnings surprise, analyst revision, or post-print price-reaction evidence is available. Low coverage and binary clinical/regulatory exposure support a monitoring stance rather than a high-conviction bullish view.